Clinical Trial Update: Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma [Phase 1]

View source ↗

Summary

Phase 1 study assessing intraventricular infusion of 5-azacytidine for recurrent posterior fossa ependymoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma

Drugs mentioned

• Vidaza (5-azacytidine) (5-azacytidine)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Recurrent Ependymoma | Phase 1 | Status: COMPLETED